The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 6, pp. 1042-1057. DOI 10.1345/aph.10264
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCart, G.
Right arrow Articles by Kayser, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCart, G.
Right arrow Articles by Kayser, S.


Research Articles

Therapeutic equivalency of low-molecular-weight heparins

GM McCart and SR Kayser

OBJECTIVE: To review the recent literature on the approved uses of enoxaparin, dalteparin, ardeparin, and tinzaparin and the evidence for therapeutic equivalence. DATA SOURCES: A MEDLINE search (1993-January 2001) was conducted to identify English-language literature available on enoxaparin, dalteparin, ardeparin, and tinzaparin. STUDY SELECTION: All controlled trials evaluating low-molecular-weight heparins (LMWHs) versus standard therapy powered to detect a significant difference were reviewed. DATA EXTRACTION: Agents were reviewed with regard to safety and efficacy. DATA SYNTHESIS: As a class, LMWHs have chemical, physical, and clinical similarities. LMWHs have greater bioavailability, longer half-lives, a more predictable pharmacologic response, possible improved safety, and similar or greater efficacy compared with unfractionated heparin (UFH). Because of this, enoxaparin, dalteparin, ardeparin, and tinzaparin are being considered as alternatives to UFH or warfarin, and there is potential for therapeutic interchange. Evaluation of clinical trials is limited because of differing diagnostic methods, drug administration times, dose equivalencies, and outcome measurements. CONCLUSIONS: Only 1 trial has evaluated 2 LMWHs in a direct comparison in the same study. There is insufficient evidence for determining the therapeutic equivalence of LMWHs.


This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
J. Fareed, W. Jeske, D. Fareed, M. Clark, R. Wahi, C. Adiguzel, and D. Hoppensteadt
Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?
Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 385 - 392.
[Abstract] [PDF]


Home page
Am J Health Syst PharmHome page
A. F. Shorr, M. W. Sarnes, P. J. Peeples, R. H. Stanford, L. E. Happe, and E. Farrelly
Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery
Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2349 - 2355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Varki
Trousseau's syndrome: multiple definitions and multiple mechanisms
Blood, September 15, 2007; 110(6): 1723 - 1729.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
S. S. Nathan, K. A. Simmons, P. P. Lin, L. E. Hann, C. D. Morris, E. A. Athanasian, P. J. Boland, and J. H. Healey
Proximal Deep Vein Thrombosis After Hip Replacement for Oncologic Indications
J. Bone Joint Surg. Am., May 1, 2006; 88(5): 1066 - 1070.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
W. Leong and D. A. Hoppensteadt
Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations
Clinical and Applied Thrombosis/Hemostasis, October 1, 2003; 9(4): 293 - 297.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.